CSW Therapeutics Awarded Second MedTech4Health Grant to Advance Clinical Readiness
Our accelerator company CSW Therapeutics has reached an important new milestone, having been awarded its second MedTech4Health grant. A strong validation of both the company’s progress and its long-term potential in cardiovascular innovation.
In 2024, CSW Therapeutics received its first MedTech4Health grant, which supported early-stage product development. That initial funding played a critical role in laying the company’s technical and organizational foundation. With the support of the grant, CSW Therapeutics built a strong, multidisciplinary team with deep expertise in acoustic measurement, testing environments, and medical technology development.
Advancing a Novel, Non-Invasive Therapy
CSW Therapeutics is developing a non-invasive cardiac soundwave therapy aimed at regenerating heart tissue and treating refractory angina, it is a condition affecting patients with limited or no remaining treatment options.
The therapy is designed to harness the power of sound to stimulate blood flow and tissue regeneration, with the ultimate goal of improving quality of life for patients who currently face significant unmet medical needs. By avoiding invasive procedures, the solution has the potential to reduce patient risk while opening new pathways for cardiac care.
A Second Grant Supporting the Next Phase
The newly awarded second MedTech4Health grant marks a significant step forward for the company. This funding will specifically support the development of CSW Therapeutics’ regulatory strategy and the planning of future clinical studies—both critical components as the company moves closer to clinical validation.
“We are now pleased to share that CSW Therapeutics has been awarded a second MedTech4Health grant, which will support the development of their regulatory strategy and planning for future clinical studies,” says Mena Nadum, CEO of CSW Therapeutics.
This phase represents a transition from early technical development toward clinical and regulatory readiness, bringing the company closer to real-world patient impact.
Receiving a second MedTech4Health grant is not only a financial boost, but also a strong external endorsement of CSW Therapeutics’ scientific approach and execution capability. It signals confidence in the company’s direction and strengthens its position as it enters the next stage of growth.
We are proud to support CSW Therapeutics on this journey and look forward to following their continued progress as they advance toward clinical studies and broader market impact.
Related Portfolio Companies
Treating heart disease with the power of sound
CSW Therapeutics is developing a non-invasive cardiac soundwave therapy designed to regenerate heart tissue and treat refractory angina. We harness the power of sound to restore blood flow and improve quality of life for patients with limited treatment options.
